Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Albuterol dry powder inhaler
Albuterol dry inhaler · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Albuterol dry powder inhaler | EXPERIMENTAL | The participants will receive albuterol delivered with the a DPI (dry powder inhaler) and placebo with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler). |
| Albuterol HFA MDI | ACTIVE_COMPARATOR | The participants will receive albuterol delivered with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler) and placebo with albuterol in a DPI (dry powder inhaler). |
| Name | Type | Description |
|---|---|---|
| Albuterol dry powder inhaler | DRUG | Albuterol DPI (dry powder inhaler) delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol will be given on two treatment days (3 to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol in a DPI (dry Powder inhaler) and albuterol in an HFA MDI (hydrofluoroalkane metered dose inhaler), ProAir. One inhaler will contain active drug and one inhaler will contain placebo. |
| Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) | DRUG | Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) delivers 90mcg of albuterol with each inhalation. Albuterol will be given on two treatment days (3to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol DPI (dry powder inhaler) and the comparator inhaler, albuterol HFA MDI (hydrofluoroalkane metered dose inhaler).One inhaler will contain active drug and one inhaler will contain placebo. |
Inclusion Criteria: * Must provide written informed consent, * Must be between 18-45 years of age, * Male or Female, females of non-child bearing potential or using reliable contraception * Asthma for at least 6 months, FEV1 (forced expiratory volume in 1 second) between 50-80% of predicted value, ...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Albuterol dry inhaler is an investigational dry powder formulation of albuterol, a small molecule bronchodilator being developed by Teva Pharmaceutical Industries Limited for asthma. It is delivered as a dry powder rather than as a liquid aerosol, and it is in Phase 1 clinical development.
Albuterol dry inhaler is being studied for the treatment of asthma. The single reported trial enrolled adults with asthma in the United States. Because the program remains in Phase 1, the formulation is investigational and has not been established as a marketed treatment option for asthma.
Albuterol dry inhaler targets ADRB2, the beta-2 adrenergic receptor. It acts as an agonist at this receptor, which is the same target class as conventional albuterol products. The dry powder formulation is designed to deliver the same active small molecule through a different inhalation device.
Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA, is the developer of the albuterol dry powder inhaler. The company sponsored the Phase 1 study that evaluated the formulation in adults with asthma.
Albuterol dry inhaler is in Phase 1 development. It is an investigational product and is not described as approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this formulation.
Albuterol dry inhaler has been studied in one completed Phase 1 trial, NCT01056159, titled A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI. It was randomized, double blind, active controlled, enrolled 47 adults with asthma in the United States, and has completed.
Yes, albuterol dry inhaler and albuterol dry powder inhaler refer to the same product. Both names describe the Teva Pharmaceutical Industries Limited formulation that delivers albuterol as a dry powder for inhalation in asthma.